Royalty Pharma (FRA:RPD) Interest Received


FRA:RPD Royalty Pharma PLC FRA:RPD
70 GF Score
Price €48.51
GF Value €32.06
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:RPD
70GF Score
Royalty Pharma PLC FRA:RPD
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €48.51 is trading 51.3% above its estimated GF Value™ of €32.06. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

  • Interest Received:
  • GF Value™: €32.06 vs. price of €48.51 (51.3% above fair value)
  • GF Score™: 70/100 with 10 warning signs

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USA
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
70GF Score

Get the complete analysis for FRA:RPD

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.51
Price
€32.06
GF Value